HRP20110365T1 - Kombinacija azd2171 i pemetrekseda - Google Patents

Kombinacija azd2171 i pemetrekseda Download PDF

Info

Publication number
HRP20110365T1
HRP20110365T1 HR20110365T HRP20110365T HRP20110365T1 HR P20110365 T1 HRP20110365 T1 HR P20110365T1 HR 20110365 T HR20110365 T HR 20110365T HR P20110365 T HRP20110365 T HR P20110365T HR P20110365 T1 HRP20110365 T1 HR P20110365T1
Authority
HR
Croatia
Prior art keywords
azd2171
pemetrexed
human
pharmaceutically acceptable
warm
Prior art date
Application number
HR20110365T
Other languages
English (en)
Inventor
Robert Wedge Stephen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0526132A external-priority patent/GB0526132D0/en
Priority claimed from GB0610708A external-priority patent/GB0610708D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HRP20110365T1 publication Critical patent/HRP20110365T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Ink Jet (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Upotreba AZD2171 ili njegove farmaceutski prihvatljive soli i pemetrekseda, naznačena time da je za proizvodnju lijeka za upotrebu kod liječenja raka kod toplokrvne životinje kao što je čovjek. Patent sadrži još 7 patentnih zahtjeva.

Claims (8)

1. Upotreba AZD2171 ili njegove farmaceutski prihvatljive soli i pemetrekseda, naznačena time da je za proizvodnju lijeka za upotrebu kod liječenja raka kod toplokrvne životinje kao što je čovjek.
2. Upotreba AZD2171 ili njegove farmaceutski prihvatljive soli i pemetrekseda, naznačena time da je za proizvodnju lijeka za upotrebu kod liječenja tumora kod toplokrvne životinje kao što je čovjek.
3. Upotreba AZD2171 ili njegove farmaceutski prihvatljive soli i pemetrekseda, naznačena time da je za proizvodnju lijeka za upotrebu kod liječenja raka kod toplokrvne životinje kao što je čovjek koji je tretiran sa ionizirajućim zračenjem.
4. Upotreba AZD2171 ili njegove farmaceutski prihvatljive soli i pemetrekseda, naznačena time da je za proizvodnju lijeka za upotrebu kod liječenja tumora kod toplokrvne životinje kao što je čovjek koji je tretiran sa ionizirajućim zračenjem.
5. Upotreba prema zahtjevu 2 ili zahtjevu 4 naznačena time da tumor je maligni pleuralni mezoteliom ili je tumor pluća nemalih stanica ili je tumor pluća malih stanica.
6. Upotreba prema zahtjevu 1 ili zahtjevu 3 naznačena time da rak je karcinom pluća nemalih stanica (NSCLC) ili maligni pleuralni mezoteliom ili karcinom pluća malih stanica (SCLC).
7. Farmaceutski pripravak naznačen time da sadrži AZD2171 ili njegovu farmaceutski prihvatljivu sol, i pemetreksed u kombinaciji sa farmaceutski prihvatljivom pomoćnom tvari ili nosačem.
8. Kit naznačen time da sadrži AZD2171 ili njegovu farmaceutski prihvatljivu sol, i pemetreksed.
HR20110365T 2005-12-22 2011-05-18 Kombinacija azd2171 i pemetrekseda HRP20110365T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0526132A GB0526132D0 (en) 2005-12-22 2005-12-22 Combination Therapy
GB0610708A GB0610708D0 (en) 2006-05-31 2006-05-31 Combination therapy
PCT/GB2006/004768 WO2007071970A2 (en) 2005-12-22 2006-12-19 Combination of azd2171 and pemetrexed

Publications (1)

Publication Number Publication Date
HRP20110365T1 true HRP20110365T1 (hr) 2011-06-30

Family

ID=37964934

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110365T HRP20110365T1 (hr) 2005-12-22 2011-05-18 Kombinacija azd2171 i pemetrekseda

Country Status (20)

Country Link
US (1) US20080306094A1 (hr)
EP (1) EP1965801B1 (hr)
JP (1) JP2009520787A (hr)
KR (1) KR20080077678A (hr)
AT (1) ATE502641T1 (hr)
AU (1) AU2006328201B2 (hr)
BR (1) BRPI0620118A2 (hr)
CA (1) CA2631676A1 (hr)
CY (1) CY1111482T1 (hr)
DE (1) DE602006020919D1 (hr)
DK (1) DK1965801T3 (hr)
HK (1) HK1123976A1 (hr)
HR (1) HRP20110365T1 (hr)
IL (1) IL191797A0 (hr)
NO (1) NO20082566L (hr)
NZ (1) NZ568812A (hr)
PL (1) PL1965801T3 (hr)
PT (1) PT1965801E (hr)
SI (1) SI1965801T1 (hr)
WO (1) WO2007071970A2 (hr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
WO2005092384A2 (en) * 2004-03-23 2005-10-06 Astrazeneca Ab Combination therapy with azd2171 and a platinum anti-tumour agent
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
WO2007003933A2 (en) * 2005-07-06 2007-01-11 Astrazeneca Ab Combination therapy of cancer with azd2171 and gemcitabine
SI1971338T1 (sl) * 2005-12-22 2011-06-30 Astrazeneca Ab Kombinacija ZD6474 in pemetrekseda
US20090221615A1 (en) * 2008-02-29 2009-09-03 Guru Reddy Combination anti-cancer agents
ES2727273T3 (es) 2010-03-08 2019-10-15 Spectrum Pharmaceuticals Inc Terapias inhibidoras de la autofagia basadas en tioxantina para tratar el cáncer
KR20180059430A (ko) * 2015-07-30 2018-06-04 익스프레션 패톨로지, 인크. 최적의 암 치료를 위한 FR-α 및 GART 단백질의 정량화

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU762615B2 (en) * 1998-06-15 2003-07-03 Arch Development Corporation Combination of radiotherapy and anti-angiogenic factors
EE05345B1 (et) * 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0316123D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0330002D0 (en) * 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
WO2005092384A2 (en) * 2004-03-23 2005-10-06 Astrazeneca Ab Combination therapy with azd2171 and a platinum anti-tumour agent
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
WO2005117980A1 (en) * 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
AU2005288736B2 (en) * 2004-09-27 2008-08-14 Astrazeneca Ab Cancer combination therapy comprising AZD2171 and imatinib
WO2007003933A2 (en) * 2005-07-06 2007-01-11 Astrazeneca Ab Combination therapy of cancer with azd2171 and gemcitabine
BRPI0619853A2 (pt) * 2005-12-15 2016-08-23 Astrazeneca Ab combinação, composição farmacêutica, e, métodos de antagonização da atividade biológica, de tratamento de angiogênese relacionada à doença em um mamífero e de tratamento de câncer em um mamífero
SI1971338T1 (sl) * 2005-12-22 2011-06-30 Astrazeneca Ab Kombinacija ZD6474 in pemetrekseda

Also Published As

Publication number Publication date
EP1965801B1 (en) 2011-03-23
PT1965801E (pt) 2011-05-25
BRPI0620118A2 (pt) 2011-11-01
CY1111482T1 (el) 2015-08-05
US20080306094A1 (en) 2008-12-11
WO2007071970A3 (en) 2007-08-09
AU2006328201A1 (en) 2007-06-28
HK1123976A1 (en) 2009-07-03
IL191797A0 (en) 2008-12-29
SI1965801T1 (sl) 2011-06-30
DE602006020919D1 (de) 2011-05-05
PL1965801T3 (pl) 2011-07-29
NZ568812A (en) 2011-09-30
WO2007071970A2 (en) 2007-06-28
DK1965801T3 (da) 2011-06-14
ATE502641T1 (de) 2011-04-15
EP1965801A2 (en) 2008-09-10
KR20080077678A (ko) 2008-08-25
NO20082566L (no) 2008-07-31
JP2009520787A (ja) 2009-05-28
CA2631676A1 (en) 2007-06-28
AU2006328201B2 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
HRP20110360T1 (hr) Kombinacija zd6474 i pemetrekseda
HRP20110365T1 (hr) Kombinacija azd2171 i pemetrekseda
DK1551409T3 (da) Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer
MX2007003506A (es) Terapia de combinacion de cancer que comprende azd2171 e imatinib.
JP2006500346A5 (hr)
HRP20080597T3 (hr) Kombinirana terapija raka koja obuhvaća azd2171 izd1839
HK1096023A1 (en) Combination therapy with azd2171 and 5-fu and/or cpt-11 azd2171?5-fu?cpt-11
MXPA05008583A (es) Terapia de combinacion de zd6474 con 5-fu y/o cpt-11.
NO20056171L (no) Kombinasjonsterapi
WO2007003933A3 (en) Combination therapy of cancer with azd2171 and gemcitabine
BR0315087A (pt) Métodos para a produção de um efeito de dano vascular em um animal de sangue quente e para o tratamento de câncer envolvendo um tumor sólido em um animal de sangue quente, composição farmacêutica, kit, e, uso de zd6126 ou um sal deste farmaceuticamente aceitável e gencitabina